Aquestive Therapeutics (NASDAQ:AQST) Shares Down 4.4% – What’s Next?

Posted by Stanley Muller on Aug 29th, 2026

Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Free Report)’s share price traded down 4.4% on Thursday . The stock traded as low as $5.18 and last traded at $5.1550. 837,966 shares traded hands during trading, a decline of 73% from the average daily volume of 3,103,022 shares. The stock had previously closed at $5.39.

Wall Street Analyst Weigh In

Several research firms recently commented on AQST. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. Wall Street Zen lowered Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a report on Monday, August 24th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $8.80.

Check Out Our Latest Stock Report on Aquestive Therapeutics

Aquestive Therapeutics Price Performance

The company has a market capitalization of $630.06 million, a PE ratio of -7.72 and a beta of 1.49. The business’s 50 day simple moving average is $4.24 and its 200 day simple moving average is $4.16.

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The firm had revenue of $13.82 million for the quarter, compared to analyst estimates of $11.42 million. As a group, analysts anticipate that Aquestive Therapeutics, Inc. will post -0.5 EPS for the current year.

Insiders Place Their Bets

In related news, Director Julie Krop sold 25,000 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total value of $125,500.00. Following the completion of the transaction, the director directly owned 25,000 shares in the company, valued at approximately $125,500. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.81% of the company’s stock.

Hedge Funds Weigh In On Aquestive Therapeutics

Several large investors have recently modified their holdings of the business. NewEdge Advisors LLC acquired a new stake in shares of Aquestive Therapeutics during the 3rd quarter worth about $28,000. BNP Paribas Financial Markets raised its holdings in Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after buying an additional 4,134 shares during the period. ADAR1 Capital Management LLC lifted its position in Aquestive Therapeutics by 103.9% in the first quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock valued at $42,000 after buying an additional 264,000 shares during the last quarter. Modern Wealth Management LLC acquired a new position in Aquestive Therapeutics in the second quarter valued at about $33,000. Finally, Elevation Point Wealth Partners LLC purchased a new position in Aquestive Therapeutics during the first quarter worth about $42,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

(Get Free Report)

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.